June 9th – 10th, 2016 | Rand Corporation, Santa Monica, California Dr. Ware participated in the 2-day celebration of the 40th anniversary of the RAND Health Insurance Experiment (HIE), the largest health policy study in U.S. history. He reunited with his colleagues on the HIE research team and others at RAND’s Santa Monica headquarters for discussions about how this landmark study has changed the health policy landscape over the last few decades.

October 24-27, 2012 | Budapest, Hungary Dr. Ware presented a paper entitled “Evaluation of a More Comprehensive Survey Item Bank for Standardizing Disease-Specific Impact Comparisons across Chronic Conditions”, at the ISOQOL Annual Conference. The paper presented a new Quality of Life Disease Impact Scale (QDIS®) developed by JWRG to fill the gap between widely-used disease-specific and generic patient-reported outcomes (PRO) measures. Preliminary evaluations of QDIS psychometric properties and empirical validity were reported. QDIS metrics standardized across conditions were shown to be sound psychometrically and valid. Combined with norm-based scoring and an integrated “dashboard” display, QDIS allows for easier interpretation of both disease-specific and generic health outcome measures. Tests of the usefulness of such combined information in clinical research and practice are warranted. In addition, Dr. Ware’s afternoon workshop at ISOQOL addressed “Integrating and Improving Generic and Disease-Specific Assessments.” Objectives included showing how both the content and scoring of disease-specific QOL impact measures can be standardized, how to evaluate improvements in QOL impact survey efficiency, and how reduced respondent burden can be achieved without sacrificing reliability and validity.

August 25th – 28th, 2013 | Montreal, Canada Including the patient’s voice in measuring risks and benefits was the topic of the plenary presentation by Dr. Ware and others at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal Convention Center, Montreal, Canada on August 25th, 2013. The goal of the presentations was to present new initiatives to better understand the patient’s voice regarding the safety and effectiveness of pharmaceutical products in real world use. Dr. Ware opened the session with a presentation entitled “Improving Disease-specific and Generic Patient-reported Outcome (PRO) Measures to Better Capture the Beneficial and Adverse Effects of Pharmaceutical Therapies” in which a comprehensive endpoint model was applied to both validating PROs and evaluating treatment PRO benefits. Included was an example of the construct (convergent-discriminant) validation of the Quality of Life Disease Impact Scale (QDIS®), a new approach to standardizing both the content and scoring of the QOL impact attributed to specific conditions. More information can be found here.